| Dr Frances Ying-nok Wong, MD | |
|
5800 Foremost Dr Se Ste 200, Grand Rapids, MI 49546-7062 | |
| (616) 389-1800 | |
| (616) 389-1839 |
| Full Name | Dr Frances Ying-nok Wong |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 17 Years |
| Location | 5800 Foremost Dr Se Ste 200, Grand Rapids, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568641074 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 4301097466 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Spectrum Health | Grand rapids, MI | Hospital |
| Mercy Health Saint Mary's | Grand rapids, MI | Hospital |
| Spectrum Health United Hospital | Greenville, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cancer And Hematology Centers Of Western Mi, P.c. | 4082526793 | 86 |
News Archive
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
Today's headlines include reports about new polling insights regarding the presidential campaign and Medicare, as well as what might become of the House of Representatives.
Dr. Mary Meengs remembers the days, a couple of decades ago, when pharmaceutical salespeople would drop into her family practice in Chicago, eager to catch a moment between patients so they could pitch her a new drug.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.
In a new publication from Cardiovascular Innovations and Applications, Wen-Yuan Ding, Jia-Min Li, Fei Zheng, Li-Li Wang, Xin-Yi Wei and Guo-Hua Li from Shandong Provincial Qianfoshan Hospital, Ji'nan, China, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji'nan, China and Shandong First Medical University, Tai'an, China consider the challenges of treating acute myocardial infarction due to variant angina.
› Verified 3 days ago
| Entity Name | Cancer & Hematology Centers Of Western Mi, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528018389 PECOS PAC ID: 4082526793 Enrollment ID: O20031103000091 |
News Archive
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
Today's headlines include reports about new polling insights regarding the presidential campaign and Medicare, as well as what might become of the House of Representatives.
Dr. Mary Meengs remembers the days, a couple of decades ago, when pharmaceutical salespeople would drop into her family practice in Chicago, eager to catch a moment between patients so they could pitch her a new drug.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.
In a new publication from Cardiovascular Innovations and Applications, Wen-Yuan Ding, Jia-Min Li, Fei Zheng, Li-Li Wang, Xin-Yi Wei and Guo-Hua Li from Shandong Provincial Qianfoshan Hospital, Ji'nan, China, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji'nan, China and Shandong First Medical University, Tai'an, China consider the challenges of treating acute myocardial infarction due to variant angina.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frances Ying-nok Wong, MD 5800 Foremost Dr Se Ste 300, Grand Rapids, MI 49546-7062 Ph: (616) 954-9800 | Dr Frances Ying-nok Wong, MD 5800 Foremost Dr Se Ste 200, Grand Rapids, MI 49546-7062 Ph: (616) 389-1800 |
News Archive
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
Today's headlines include reports about new polling insights regarding the presidential campaign and Medicare, as well as what might become of the House of Representatives.
Dr. Mary Meengs remembers the days, a couple of decades ago, when pharmaceutical salespeople would drop into her family practice in Chicago, eager to catch a moment between patients so they could pitch her a new drug.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.
In a new publication from Cardiovascular Innovations and Applications, Wen-Yuan Ding, Jia-Min Li, Fei Zheng, Li-Li Wang, Xin-Yi Wei and Guo-Hua Li from Shandong Provincial Qianfoshan Hospital, Ji'nan, China, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji'nan, China and Shandong First Medical University, Tai'an, China consider the challenges of treating acute myocardial infarction due to variant angina.
› Verified 3 days ago
Maureen U Tan- Pedres, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 100 Michigan St Ne, Suite A721, Grand Rapids, MI 49503 Phone: 616-391-3139 Fax: 616-391-3044 | |
Jeffery Allen Woo, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1900 Wealthy St Se, Ste 150, Grand Rapids, MI 49506 Phone: 616-459-3158 Fax: 616-988-0071 | |
Robert W Selfe, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 221 Michigan St Ne, Suite 200, Grand Rapids, MI 49503 Phone: 616-267-8950 Fax: 616-267-8585 | |
Dr. Erin Megan Pettijohn, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 250 Cherry St Se Ste 2200, Grand Rapids, MI 49503 Phone: 616-685-5600 | |
Dr. Andrew Leo Sochacki, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5800 Foremost Dr Se Ste 200, Grand Rapids, MI 49546 Phone: 616-389-1800 | |
Stephanie F Williams, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 145 Michigan St Ne, Suite 5200, Grand Rapids, MI 49503 Phone: 616-486-5933 Fax: 616-486-6489 | |
Simin Beg, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 145 Michigan St Ne Ste 3410, Grand Rapids, MI 49503 Phone: 616-391-9945 |